SPOTLIGHT -
Cardiologist Anees A. Daud, MD, elucidates examinations and tests that help to identify cardiovascular risk in practice.
Phase 3 ARASTEP study to investigate darolutamide plus ADT for hormone-sensitive prostate cancer
"With ARASTEP, we are optimistic about the potential to help patients at this earlier stage of [prostate cancer]," says Tara Frenkl, MD.
Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer
Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.
Study evaluates polygenic risk score for prostate cancer risk prediction
“Vanderbilt researchers are participating in numerous projects related to PRS and disease risk; studies such as this highlight the importance of evaluating whether novel clinical tools actually enhance care,” said Kerry Schaffer, MD.
Dr. Laviana on decisional regret after prostate cancer treatment
“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.
ProtecT trial researchers: Active monitoring yields same outcomes as radical treatment in prostate cancer
Findings suggest many patients with localized disease can delay surgery or radiation without increasing their mortality risk.
Expert highlights the latest radiotherapy developments in prostate cancer
“As the ability to target improved, what we really clearly saw was the idea that perhaps a treatment course could be shortened significantly, and that the term hypofractionation became commonly applied to men with prostate cancer,” said Walter J. Curran Jr, MD, FACR, FASCO.